Takashi Nagawa

  • Citations Per Year
Learn More
Antiviral strategies to inhibit HIV-1 replication have included the generation of gene products that provide the intracellular inhibition of an essential viral protein or RNA. When used in conjunction with the HIV-1 long terminal repeat (LTR), an inducible promoter dependent on the virus-encoded trans-activator (tat), relatively high background activity is(More)
The cleavage of target mRNA by ribozymes is being exploited as a means of gene silencing in nucleic-acid-based therapies. We previously established an HIV-1-dependent ribozyme-expression vector system, based on Cre-loxP technology with an LTR-gag-p17 promoter as a molecular switch for use in acute HIV-1 infection. The simultaneous expression of the Cre(More)
We previously demonstrated the function of an HIV-1-dependent ribozyme expression vector, with which the site-specific excision of loxP sequences can be achieved by using the Cre-loxP system (ON/OFF) as a molecular switch in an acute HIV-1 infection. However, this expression system also revealed the lower, non-specific expression of the anti-H1V-1 ribozyme(More)
We used the HIV-1 5'LTR and the Cre/loxP system to develop an anti-gene expression system. The LTR promoter of HIV-1 has a specific activity that includes the intermediary region of gag, as shown in a previous report. We constructed the U5-region of HIV-1 as the target of the ribozyme expression vector (pCre/loxP-Rz), with the Cre/loxP system under the(More)
  • 1